SMO and medulloblastoma: This type of signaling has been observed in basal cell carcinoma (PTCH and SMO mutations)[94,95], medulloblastoma (PTCH and SUFU mutations)[96], and rhabdomyosarcoma (PTCH and SUFU loss of heterozygosity)[97].